Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast

9Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Aims Here we explore the presence of mediator complex subunit 12 (MED12) exon 2 and telomerase reverse transcriptase (TERT) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast. Methods The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and the TERT promoter hotspot loci. The epithelial and stromal components of two MED12 mutated CFAs were subjected to laser capture microdissection, and Sanger sequencing of MED12 exon 2, TERT promoter and PIK3CA exons 9 and 20, separately. Results MED12 exon 2 mutations were identified in the stroma of 17% of CFAs. The analyses of epithelial and stromal components, microdissected separately, revealed that MED12 mutations were restricted to the stroma. No TERT promoter or PIK3CA mutations in exons 9 and 20 were detected in analysed CFAs. Conclusions Like conventional fibroadenomas, MED12 exon 2 mutations appear to be restricted to the stromal component of CFAs, supporting the notion that CFAs are stromal neoplasms.

Cite

CITATION STYLE

APA

Da Silva, E. M., Beca, F., Sebastiao, A. P. M., Murray, M. P., Silveira, C., Da Cruz Paula, A., … Zhang, H. (2022). Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast. Journal of Clinical Pathology, 75(2), 133–136. https://doi.org/10.1136/jclinpath-2020-207062

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free